Trials and Fibrillations with Dr John Mandrola

 
 
  • The Power of Suggestion: Statin and Beta-blocker Side Effects A recent analysis highlights the nocebo effect in patients experiencing muscle symptoms with statin therapy. Dr Mandrola sees this brain trickery at work in patients on beta-blockers and those with atrial fibrillation.
  • Who Needs a Statin? DNA Beats Current Risk Calculators Dr Mandrola reviews the data on genetic risk scores and sees hope of finally improving our ability to predict CAD risk and which patients will benefit most from statins.
  • ECG Reading: Don't Cede Control to the Machines In the era of human vs machine, Dr Mandrola warns about the risk of fake atrial-fibrillation diagnoses from computer-read ECGs.
  • ACC Small Clots in Bioprosthetic Valves Should Slow TAVR Train Dr John Mandrola summarizes the findings of a study of the RESOLVE and SAVORY registries on subclinical thrombosis in surgical and transcatheter valve replacement.
  • ACC First Clinical Trial of CTO Procedures Fails to Deliver UPDATED // Given the rise of procedures for chronic total coronary occlusions, Dr. Mandrola feels that the decidedly negative DECISION-CTO trial is the most important study from the second day of ACC.
  • ACC Ten Quick Thoughts on FOURIER Dr Mandrola attended the late-breaking session at ACC and has these 10 quick thoughts on the landmark FOURIER trial.
  • ACC Mandrola Previews ACC 2017 Dr John Mandrola perused the program for the upcoming American College of Cardiology Scientific Sessions in Washington, DC. Read about the studies and lectures that caught his eye.
  • Contrast-Induced Nephropathy: Signal or Noise? A study showing similar rates of contrast-induced nephropathy with or without hydration challenges expert opinion. Dr Mandrola quotes a nephrologist who asks if we need to rethink CIN entirely.
  • 10 Highlights from the 10th Annual Western AF Symposium A quick roundup of Dr Mandrola’s picks from the recent atrial fibrillation conference cosponsored by the University of Utah and the Heart Rhythm Society.
  • NOACs Are Favored Over Warfarin: I'm (Almost) Okay With That Clinical experience with the new direct-acting oral anticoagulants (DOACs or NOACs) is reassuring, says Dr Mandrola, but independent confirmatory analysis of the data would be even better.
  • ICDs in the Elderly With VT/VF: Be a Doctor Not an Implanter In older-aged survivors of ventricular arrhythmia, there are other outcomes besides mortality to factor in the decision to use an ICD, explains Dr John Mandrola.
  • A Career in Cardiology: Advice From an EP In a letter to medical students, Dr Mandrola looks back on 20 years as an electrophysiologist and asks if he would choose the same specialty today.
  • STS Guidelines Wrong to Call for More Surgical AF Ablation The new Society of Thoracic Surgeons guidelines on atrial fibrillation conclude that more frequent surgical ablation may improve patient outcomes, but the data suggest otherwise, says Dr Mandrola.
  • Mandrola's Top 10 Cardiology Stories of 2016 It's that time of the year again when Dr John Mandrola makes his picks of the top stories in cardiology for 2016. Did your favorite study make the list?
  • AHA Bad Policy Is as Harmful as Bad Medicine Dr John Mandrola's take on a presentation of outcomes vs adherence to performance measures in managing patients with heart failure.
  • AHA AHA 2016: How Do NOAC Drugs Fare Against Well-Managed Warfarin? Although NOAC drugs compare favorably with warfarin in patients with AF, questions remain about the differences when warfarin is well managed. Dr Mandrola reports on a provocative observational study from Sweden, where warfarin management is superior.
  • AHA AHA: Technology Delivers Little Improvement in AF Ablation Success Despite thrilling advances in technology, a study presented at the AHA meeting reveals little progress in AF ablation success. Dr John Mandrola explores reasons for this plateau.
  • TCT Left Atrial Appendage Closure Should Stop Now Enthusiasm for left atrial appendage closure with the Watchman device is alarming to Dr Mandrola, when a close look at all the evidence does not support its efficacy for reducing ischemic events.
  • AHA Mandrola Previews AHA 2016 Dr John Mandrola takes a look at the late-breaking clinical trials and other presentations coming up at the American Heart Association Scientific Sessions this weekend in New Orleans.
  • AMI Outcomes: Excellence Is a Choice, Not a Checklist A study showing that AMI patients treated at hospitals with good short-term outcomes yield long-term benefits reminds Dr Mandrola that excellent performance is a matter of choice and not a checklist.